|
Aug 6
|
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
|
|
Jul 31
|
Here's Why VYNE Therapeutics (NASDAQ:VYNE) Must Use Its Cash Wisely
|
|
Jul 30
|
Sector Update: Health Care Stocks Decline in Late Afternoon Trading
|
|
Jul 30
|
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
|
|
Jul 11
|
VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress
|
|
Jul 2
|
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
|
|
Feb 13
|
3 US Penny Stocks To Watch With Market Caps Over $20M
|
|
Dec 31
|
US Penny Stocks To Watch In December 2024
|
|
Sep 26
|
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully
|
|
Jul 11
|
One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year
|
|
Jul 9
|
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
|
|
Jun 26
|
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
|
|
May 9
|
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 6
|
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
|
|
May 1
|
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
|
|
Apr 13
|
VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans
|
|
Mar 19
|
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
|
|
Jan 10
|
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
|
|
May 1
|
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
|